Shares of Artiva Biotherapeutics Inc. (ARTV) have more than doubled year-to-date, driven by continued progress in its lead AlloNK program.
AlloNK is an off-the-shelf cell therapy made from donor immune cells (NK cells) that are frozen and stored until needed. It helps antibody drugs work better by boosting their ability to drive deep B-cell depletion.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com